A methodical 68Ga-labelling study of DO2A-(butyl- l-tyrosine)2 with cation-exchanger post-processed 68Ga: Practical aspects of radiolabelling

Contrast Media and Molecular Imaging

Volumn 6, Issue 6, 2011, Pages 492-498

  Riss, Patrick J ^a,b   Burchardt, Carsten ^a   Roesch, Frank ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

68Ge 68Ga radionuclide generator; Amino acids; DO2A; Post processing; Radiolabelling

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,7 DIACETIC ACID 4,10 DI (O BUTYL) TYROSINE GA 68; TRACER; UNCLASSIFIED DRUG; (68GA)DO2A (BUTYLTYROSINE)2; (68GA)DO2A-(BUTYLTYROSINE)2; COORDINATION COMPOUND; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GALLIUM; RADIOPHARMACEUTICAL AGENT; TYROSINE;

ARTICLE; CATION EXCHANGE; CHEMICAL REACTION; CYCLOTRON; HEATING; ISOTOPE LABELING; MICROWAVE IRRADIATION; MOLECULAR IMAGING; PH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PURIFICATION; QUALITY CONTROL; QUANTUM YIELD; RADIOCHEMISTRY; SOLID PHASE EXTRACTION; TECHNIQUE; TEMPERATURE SENSITIVITY; TIME; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; TEMPERATURE;

COORDINATION COMPLEXES; GALLIUM RADIOISOTOPES; HUMANS; HYDROGEN-ION CONCENTRATION; ISOTOPE LABELING; MOLECULAR STRUCTURE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SOLID PHASE EXTRACTION; TEMPERATURE; TYROSINE;

EID: 83155163808     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.451     Document Type: Article

References (29)

1. 68Ga radiopharmaceutical chemistry. Curr Top Med Chem 2010; 10(16): 1633-1668.
2. 68Ga-PET: a powerful generator-based alternative to cyclotron-based radiopharmaceuticals. Contrast Media Mol Imag 2008; 3: 67-77; doi: 10.1002/cmmi.232
3. 68Ga-labelling under anhydrous conditions. Radiochim Acta 2010; 98: 157-160; doi: 10.1524/ract.2010.1698
4. 111In-labelled transferrin in vitro. Protein Pept Lett 2009; 16: 138-142.
5. 68Ga-Citrate PET/CT for evaluating patients with infections of the bone: Preliminary results. J Nucl Med 2010; 51: 1932-1936; doi: 10.2967/jnumed.110.080184
6. 67Ga citrate. J Nucl Med 1969; 10: 103-105.
7. Sundberg MW, Meares CF, Goodwin DA, Diamanti CI. Selective binding of metal ions to macromolecules using bifunctional analogs of EDTA. J Med Chem 1974; 17: 1304-1308; doi: 10.1021/jm00258a015
8. Brechbiel MW, Gansow OA, Atcher RW, Schlom J, Esteban J, Simpson D, Colcher D. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labelling and tumor-imaging studies. Inorg Chem 1986; 25: 2772-2781; doi: 10.1021/ic00236a024
9. De Leon-Rodriguez LM, Kovacs Z. The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjug Chem 2008; 19: 391-402; doi: 10.1021/bc700328s
10. André J, Maecke H, Zehnder M, Macko L, Akyel K. 1, 4, 7-triazanonane-1-succinic acid-4, 7-diacetic acid (NODASA): a new bifunctional chelator for radio gallium-labeling of biomolecules. Chem Commun 1998; 12: 1301-1302; doi: 10.1039/A801294F
11. 68Ga-radiolabelling and in vitro characterisation of novel versatile chelators for molecular imaging. Bioorg Med Chem Lett 2008; 18: 5364-5367; doi: 10.1016/j.bmcl.2008.09.054
12. Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, Rubello D. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res 2007; 27: 4087-4094.
13. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002; 13: 530-541; doi: 10.1021/bc010074f
14. 68Ga-labelled peptides in tumor imaging. J Nucl Med 2005; 46: 172S-178S.
15. Haubner R, Decristoforo C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front Biosci 2009; 14: 872-886.
16. 68Ga-labelled NOTA-RGD-BBN for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imag 2009; 36: 1483-1494; doi: 10.1007/s00259-009-1123-z
17. Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imag 2011; 38(1): 97-107.
18. 68Ga-DO2A-tyrosine conjugate as potential tumor tracer for PET. Bioorg Med Chem Lett 2009; 19: 3498-3501; doi: doi:10.1016/j.bmcl.2009.05.001
19. 68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass. Nucl Med Biol 2010; 37: 265-275; doi: 10.1016/j.nucmedbio.2009.11.008
20. 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug Chem 2008; 19: 569-573; doi: 10.1021/bc700341x
21. Hume SP, Myers R. 2002. Dedicated small animal scanners: a new tool for drug development? Curr Pharm Des 8: 1497-1511.
22. Jagoda EM, Vaquero JJ, Seidel J, Green MV, Eckelman WC. 2004. Experiment assessment of mass effects in the rat: Implications for small animal PET imaging. Nucl Med Biol 31: 771-779.
23. Aime S, Geninatti Crich S, Gianolio E, Giovenzana GB, Tei L, Torreno E. High sensitivity lanthanide(III) based probes for MR-medical imaging. Coord Chem Rev 2006; 250: 1562-1579; doi: 10.1016/j.ccr.2006.03.015
24. 68Ga. Eur J Nucl Med Mol Imag 2005; 32: 478-485; doi: 10.1007/s00259-004-1702-y
25. 68Ga-labelled DOTA-drivatised peptide ligands. Eur J Nucl Med Mol Imag 2004; 31: 1097-1104; doi: 10.1007/s00259-004-1486-0
26. 68Ga for medical application. J Nucl Med 2007; 48: 1741-1748; doi: 10.2967/jnumed.107.040378
27. 68Ga-DOTATOC. Nucl Med Biol 2008; 35: 721-724; doi: 10.1016/j.nucmedbio.2008.04.006
28. Green AM, Welch MJ. Gallium radiopharmaceutical chemistry. Int J Radiat Appl Instrum Pt B 1989; 16: 435-448.
29. 68Ga-bioconjugates with high specific activity. Bioconjug Chem 2004; 15: 554-560; doi: 10.1021/bc030078f